The Complete Evidence-Based Guide to Stem Cell Therapy, Functional HIV Cure Cases, CCR5 Mutation, Gene Editing, Clinical Trials and the Future of HIV Treatment
🧬 Introduction
For more than four decades, Human Immunodeficiency Virus (HIV) has remained one of the world’s most significant infectious diseases. Since its identification in the early 1980s, remarkable advances in diagnosis, prevention and treatment have transformed HIV from a frequently fatal condition into a manageable chronic disease for millions of people. Modern antiretroviral therapy (ART) enables most individuals living with HIV to achieve long-term viral suppression, restore immune function and maintain a life expectancy approaching that of the general population.
Despite these extraordinary achievements, a definitive cure remains one of the greatest challenges in modern medicine.
The primary obstacle is the virus’s ability to establish latent viral reservoirs—long-lived cells in which HIV integrates its genetic material and remains dormant, escaping both the immune system and currently available medications. As a result, lifelong treatment is still necessary for most people living with HIV.
In recent years, however, a small number of extraordinary clinical cases have changed the scientific landscape. Individuals known as the Berlin Patient, London Patient, and Düsseldorf Patient achieved long-term HIV remission following hematopoietic stem cell transplantation from donors carrying the rare CCR5-Δ32 genetic mutation. Although these procedures were performed to treat life-threatening blood cancers rather than HIV itself, they provided the first compelling evidence that a functional cure for HIV may be biologically possible under exceptional circumstances.
These landmark discoveries have accelerated global research into innovative therapeutic strategies, including stem cell therapy, gene editing (CRISPR), engineered immune cells, broadly neutralizing antibodies, therapeutic vaccines, and other advanced immunotherapies. Rather than relying on a single intervention, many researchers now believe that combining multiple approaches may offer the most promising path toward long-term HIV remission without lifelong antiretroviral therapy.
It is important to emphasize that stem cell transplantation is not a standard treatment for HIV. The procedure carries significant risks, requires highly specialized medical centers, and is currently considered only for selected patients who also require transplantation to treat serious hematologic diseases. Consequently, the remarkable remission cases reported to date should not be interpreted as evidence that stem cell transplantation is an appropriate therapy for the broader population of people living with HIV.
This comprehensive evidence-based review examines the current scientific understanding of stem cell therapy for HIV, the biological mechanisms underlying the reported functional cure cases, the role of the CCR5-Δ32 mutation, the latest clinical trials, emerging gene-editing technologies, and the future directions of HIV cure research. By critically analyzing the available evidence, this article aims to distinguish established scientific knowledge from ongoing experimental research while providing healthcare professionals, researchers, students and readers with an accurate, balanced and up-to-date overview of one of the most rapidly evolving fields in infectious disease and regenerative medicine.
Evidence-Based Clinical Perspective: While modern antiretroviral therapy remains the cornerstone of HIV treatment, advances in stem cell biology, immunology and gene editing continue to expand our understanding of what may one day become a safe, scalable and widely accessible strategy for achieving long-term HIV remission or cure.
📑 Scientific Roadmap
Explore the scientific journey through HIV biology, stem cell therapy, functional cure cases, gene editing, emerging clinical trials and the future of HIV cure research.
🧬 Part 1 — Understanding HIV and Why a Cure Is So Difficult
What Is HIV?
Human Immunodeficiency Virus (HIV) is a virus that primarily attacks the immune system, specifically CD4+ T lymphocytes (helper T cells). These cells coordinate immune responses against infections and certain cancers.
Without treatment, HIV progressively destroys these immune cells, weakening the body’s defenses and increasing susceptibility to opportunistic infections and malignancies. If untreated, advanced HIV infection can progress to Acquired Immunodeficiency Syndrome (AIDS).
Today, modern antiretroviral therapy (ART) enables most people living with HIV to achieve a near-normal life expectancy by suppressing viral replication. However, ART does not eliminate the virus from the body.
🦠 How HIV Infects the Immune System
HIV follows a highly specialized life cycle:
Step 1 — Attachment
The virus binds to the CD4 receptor on helper T cells.
It then interacts with one of two co-receptors:
- CCR5 (most common during early infection)
- CXCR4 (more common in later stages)
These receptors allow HIV to enter susceptible immune cells.
Step 2 — Cell Entry
After binding, the viral envelope fuses with the cell membrane, allowing the viral RNA and enzymes to enter the host cell.
Step 3 — Reverse Transcription
Unlike human cells, HIV stores its genetic information as RNA.
Using the enzyme reverse transcriptase, HIV converts its RNA into DNA.
This step is prone to errors, generating frequent mutations that help the virus evade immune responses and contribute to drug resistance.
Step 4 — Integration
The viral DNA is transported into the nucleus, where the enzyme integrase inserts it into the host cell’s genome.
Once integrated, the virus becomes part of the infected cell’s genetic material.
Step 5 — Viral Production
The infected cell begins producing new viral proteins and RNA, assembling new HIV particles.
Step 6 — Release and Maturation
New viral particles bud from the cell.
The enzyme protease processes viral proteins, producing mature infectious viruses capable of infecting additional cells.
🧬 Viral Reservoirs: The Greatest Barrier to Cure
One of the greatest challenges in HIV medicine is the existence of viral reservoirs.
These are long-lived cells containing integrated HIV DNA that remain in a dormant (latent) state.
Because the virus is not actively replicating inside these cells, neither the immune system nor antiretroviral drugs can eliminate them.
Common reservoirs include:
- Resting memory CD4+ T cells
- Lymph nodes
- Gut-associated lymphoid tissue (GALT)
- Spleen
- Central nervous system
- Macrophages and other long-lived immune cells
Even after many years of successful treatment, these reservoirs can reactivate if therapy is interrupted, leading to viral rebound.
💊 Why Antiretroviral Therapy Cannot Eliminate HIV
Modern ART targets active stages of the viral life cycle.
Different drug classes block different steps:
- Entry inhibitors
- CCR5 antagonists
- Fusion inhibitors
- Reverse transcriptase inhibitors
- Integrase inhibitors
- Protease inhibitors
These medications are highly effective at suppressing viral replication.
However, they cannot remove HIV DNA that has already integrated into the genome of resting cells.
For this reason:
- Viral load may become undetectable.
- Transmission risk is effectively eliminated when viral suppression is maintained (“Undetectable = Untransmittable”, or U=U).
- The latent virus persists.
- Lifelong treatment is currently required for most people.
📈 Current Treatment Successes and Limitations
The management of HIV has improved dramatically over the past four decades.
Major achievements
- ✅ Life expectancy approaches that of the general population with early diagnosis and consistent treatment.
- ✅ Once-daily combination therapies simplify adherence.
- ✅ Long-acting injectable medications reduce dosing frequency for selected patients.
- ✅ Mother-to-child transmission can often be prevented with appropriate care.
- ✅ Viral suppression prevents sexual transmission when maintained.
Remaining challenges
- ❌ No widely available cure.
- ❌ Persistent viral reservoirs.
- ❌ Lifelong adherence is usually necessary.
- ❌ Drug resistance may develop if treatment is interrupted or inconsistent.
- ❌ Access to diagnosis and treatment remains unequal in many parts of the world.
🔑 Key Takeaways
- HIV primarily infects CD4+ T lymphocytes and integrates its genetic material into host cells.
- Antiretroviral therapy effectively suppresses viral replication but does not eradicate latent viral reservoirs.
- Viral reservoirs are the principal obstacle to a definitive cure.
- Rare cases of functional HIV cure following hematopoietic stem cell transplantation have provided valuable insights for research but do not represent a standard treatment approach.
- Current research focuses on eliminating or permanently silencing viral reservoirs through strategies such as stem cell therapy, gene editing, immunotherapy, and therapeutic vaccines.
🧬 Part 2 — Stem Cell Therapy and the Functional Cure of HIV
Introduction to Stem Cell Transplantation
Stem cell transplantation is a medical procedure used primarily to treat certain blood cancers and severe hematological disorders, including leukemia, lymphoma, multiple myeloma, and some inherited immune diseases.
In HIV research, stem cell transplantation gained worldwide attention after a small number of individuals achieved long-term HIV remission following transplantation from donors carrying a rare genetic mutation known as CCR5-Δ32.
Importantly, these procedures were performed to treat life-threatening blood cancers—not HIV itself. The apparent HIV remission was an unexpected and scientifically valuable outcome.
🩸 Hematopoietic Stem Cell Transplantation (HSCT)
Hematopoietic stem cells are immature cells capable of generating all blood and immune cells.
They are found in:
- Bone marrow
- Peripheral blood
- Umbilical cord blood
HSCT replaces a patient’s diseased immune system with healthy donor stem cells.
The process generally involves:
Step 1 — Conditioning
Patients receive high-dose chemotherapy, with or without radiotherapy, to destroy diseased bone marrow and suppress the immune system.
Step 2 — Stem Cell Infusion
Healthy donor stem cells are infused intravenously.
These cells migrate naturally to the bone marrow.
Step 3 — Immune System Reconstruction
Over several weeks, donor stem cells rebuild the patient’s blood-forming and immune systems.
When the donor carries the CCR5-Δ32 mutation, many of the newly formed immune cells become highly resistant to infection by CCR5-tropic HIV strains.
🧬 The CCR5-Δ32 Mutation Explained
CCR5 is a receptor located on the surface of CD4+ T cells and certain other immune cells.
Many HIV strains use this receptor as a “doorway” to enter cells.
Individuals who inherit the CCR5-Δ32 mutation from both parents (homozygous) produce little or no functional CCR5 receptor.
As a result:
- HIV has great difficulty infecting these immune cells.
- These individuals are naturally resistant to many (but not all) HIV strains.
The mutation is uncommon worldwide and is found more frequently in people of Northern European ancestry.
🌍 The Berlin Patient
The first documented case of long-term HIV remission was reported in Timothy Ray Brown, often called the Berlin Patient.
He had:
- HIV infection.
- Acute myeloid leukemia.
His physicians performed a hematopoietic stem cell transplant using a donor who was homozygous for the CCR5-Δ32 mutation.
Following transplantation:
- Antiretroviral therapy was discontinued.
- HIV did not rebound.
- Extensive testing over many years failed to detect replication-competent virus.
This case transformed HIV cure research by demonstrating that long-term remission was biologically possible.
🇬🇧 The London Patient
The London Patient (Adam Castillejo) developed Hodgkin lymphoma while living with HIV.
He also received a stem cell transplant from a CCR5-Δ32 donor.
After carefully supervised discontinuation of antiretroviral therapy:
- HIV remained undetectable.
- Long-term follow-up supported sustained remission.
His case independently confirmed that the Berlin Patient was not an isolated event.
🇩🇪 The Düsseldorf Patient
Another landmark case involved the Düsseldorf Patient, who underwent transplantation for leukemia.
Long-term follow-up demonstrated:
- Sustained HIV remission.
- No viral rebound after stopping antiretroviral therapy under medical supervision.
- Extremely low or undetectable levels of replication-competent HIV.
Together with the Berlin and London cases, this strengthened the scientific evidence that eliminating susceptible immune cells and rebuilding the immune system with CCR5-Δ32 donor cells can, in rare circumstances, lead to durable HIV remission.
🌎 Other Reported Functional Cure Cases
Several additional patients have since been reported with prolonged HIV remission after receiving stem cell transplants from CCR5-Δ32 donors.
Although these cases differ in clinical details, common features include:
- HIV infection before transplantation.
- Treatment for a serious hematologic malignancy.
- Replacement of the immune system with donor cells resistant to many HIV strains.
- Careful interruption of antiretroviral therapy under specialist supervision.
- Long-term absence of viral rebound.
Each new case has helped researchers better understand the mechanisms that may contribute to a functional HIV cure.
⚠️ Why Stem Cell Transplants Are Not Standard HIV Therapy
Despite these remarkable successes, hematopoietic stem cell transplantation is not recommended as a routine treatment for HIV.
Several factors explain why:
- The procedure carries substantial risks, including severe infections, graft-versus-host disease, organ toxicity, and transplant-related mortality.
- Suitable donors with the CCR5-Δ32 mutation are extremely rare.
- Modern antiretroviral therapy is highly effective and allows most people with HIV to live long, healthy lives without the risks associated with transplantation.
- Not all HIV strains rely on the CCR5 receptor; some use the CXCR4 co-receptor, which may limit the effectiveness of this strategy.
For these reasons, stem cell transplantation is generally considered only when a person with HIV also requires a transplant to treat a life-threatening blood cancer.
⚖️ Risks and Ethical Considerations
Researchers emphasize that the benefits observed in these exceptional cases should not be generalized to all people living with HIV.
Key considerations include:
- High medical complexity.
- Significant risk of complications.
- Limited donor availability.
- High cost.
- Need for highly specialized transplant centers.
- Careful patient selection.
Current research aims to reproduce the beneficial effects of CCR5-Δ32 transplantation through safer and more scalable approaches, such as gene editing, engineered immune cells, therapeutic vaccines, and other targeted immunotherapies, without exposing patients to the risks of a full stem cell transplant.
🔑 Key Takeaways
- Hematopoietic stem cell transplantation has led to long-term HIV remission in a small number of exceptional cases.
- A donor carrying the CCR5-Δ32 mutation appears to be a critical factor in many of these cases.
- These procedures were performed primarily to treat blood cancers, not HIV itself.
- Because of the substantial risks and limited applicability, stem cell transplantation is not a standard treatment for HIV.
- The lessons learned from these cases continue to guide the development of safer strategies aimed at achieving a broadly applicable HIV cure.
🚀 Part 3 — The Future of HIV Cure Research
Over the past decade, HIV cure research has shifted from controlling viral replication to pursuing long-term remission or complete eradication of the virus. While antiretroviral therapy (ART) remains the standard of care, scientists are investigating innovative strategies designed to eliminate or permanently silence the virus without the need for lifelong medication.
Although no widely applicable cure currently exists, several promising approaches are advancing through preclinical and clinical research.
🧬 Gene Editing (CRISPR)
One of the most exciting areas of HIV research involves CRISPR-Cas gene editing technology.
CRISPR functions as a molecular tool capable of making highly specific modifications to DNA.
Researchers are investigating several potential applications:
- Removing integrated HIV DNA from infected cells.
- Disrupting the CCR5 gene to create HIV-resistant immune cells.
- Engineering immune cells to recognize and eliminate infected cells.
- Combining CRISPR with other antiviral therapies to reduce viral reservoirs.
Advantages
- Highly targeted approach.
- Potential for long-lasting effects.
- May complement existing HIV therapies.
Current Challenges
- Safe delivery of CRISPR to all viral reservoirs.
- Avoiding unintended genetic modifications (off-target effects).
- Ensuring long-term safety.
- Reaching latent virus hidden throughout the body.
Although encouraging laboratory and early clinical findings have been reported, CRISPR remains an investigational strategy.
🧫 Cellular Therapies
Scientists are developing cellular therapies that do not require the risks associated with bone marrow transplantation.
Potential strategies include:
- Engineering stem cells resistant to HIV.
- Expanding HIV-specific immune cells.
- Regenerating damaged immune function.
- Combining cellular therapies with gene editing.
These approaches aim to reproduce the benefits observed in rare transplant-related remission cases while improving safety and accessibility.
🛡️ Immune Cell Engineering
Advances in immunotherapy have led to the development of genetically engineered immune cells.
One promising strategy involves CAR-T cell therapy, which has already transformed the treatment of several blood cancers.
Researchers are adapting CAR-T technology to:
- Recognize HIV-infected cells.
- Destroy latent reservoirs after viral reactivation.
- Provide long-lasting immune surveillance.
Other engineered immune cell approaches are also under investigation to improve the body’s ability to control HIV without continuous medication.
🧪 Broadly Neutralizing Antibodies (bNAbs)
Broadly neutralizing antibodies (bNAbs) are naturally occurring antibodies capable of neutralizing multiple HIV variants.
Unlike conventional antibodies, bNAbs target highly conserved regions of the virus that change very little over time.
Potential applications include:
- Preventing HIV infection.
- Maintaining viral suppression.
- Delaying or preventing viral rebound after stopping ART.
- Supporting reservoir reduction when combined with other therapies.
Several bNAbs are currently being evaluated in clinical trials, both individually and in combination.
💥 Shock and Kill Strategy
One of the greatest obstacles to curing HIV is the presence of latent viral reservoirs.
The Shock and Kill strategy seeks to eliminate these hidden viruses through two sequential steps:
Step 1 — Shock
Medications activate dormant HIV hidden inside infected cells.
Once reactivated, infected cells begin producing viral proteins.
Step 2 — Kill
The immune system—or additional therapies such as antibodies, engineered immune cells, or antiviral drugs—targets and destroys these newly visible infected cells.
Potential Benefits
- Reduction of viral reservoirs.
- Possibility of durable remission.
Current Limitations
- Not all latent cells are successfully reactivated.
- Complete elimination of infected cells remains difficult.
- Risk of immune activation.
🔒 Block and Lock Strategy
Rather than activating latent HIV, the Block and Lock strategy aims to keep the virus permanently silent.
Researchers seek medications capable of locking HIV into a deep dormant state, preventing future reactivation.
If successful, patients could potentially maintain long-term viral control without continuous antiretroviral therapy.
This strategy remains under active investigation.
🌍 Ongoing Clinical Trials
Current HIV cure research includes studies evaluating:
- Gene editing technologies.
- Therapeutic vaccines.
- Broadly neutralizing antibodies.
- Immune checkpoint modulation.
- CAR-T cells.
- Combination immunotherapies.
- Novel latency-reversing agents.
- Long-acting antiviral therapies.
Many researchers believe that combination approaches are more likely to succeed than any single therapy alone.
🤖 Artificial Intelligence and Precision Medicine
Artificial intelligence (AI) is increasingly contributing to HIV research by:
- Identifying new drug targets.
- Predicting viral mutations.
- Designing optimized antibody combinations.
- Accelerating clinical trial analysis.
- Supporting personalized treatment strategies.
AI may significantly shorten the time required to identify promising therapeutic combinations.
🌅 Future Perspectives
The rare cases of long-term HIV remission following stem cell transplantation have demonstrated that a functional cure is biologically possible under exceptional circumstances.
The next generation of HIV cure research aims to achieve similar outcomes using safer, scalable, and more accessible therapies.
Future strategies will likely combine:
- Gene editing.
- Cellular engineering.
- Immunotherapy.
- Therapeutic vaccines.
- Broadly neutralizing antibodies.
- Long-acting antivirals.
- Artificial intelligence–guided precision medicine.
Although significant scientific and technical challenges remain, advances in these fields continue to improve our understanding of HIV persistence and bring researchers closer to the goal of long-term remission without lifelong therapy.
🔑 Key Takeaways
- Gene editing technologies such as CRISPR may help create HIV-resistant immune cells or target integrated viral DNA.
- Cellular engineering and CAR-T therapies seek to enhance the immune system’s ability to recognize and eliminate infected cells.
- Broadly neutralizing antibodies show promise for preventing viral rebound and supporting reservoir reduction.
- “Shock and Kill” and “Block and Lock” represent two complementary strategies to address latent HIV reservoirs.
- No investigational cure has yet become standard clinical practice, but ongoing research is advancing rapidly and increasingly focuses on combination therapies that balance effectiveness and safety.
- The long-term goal is to develop a cure strategy that is effective, safe, scalable, and applicable to the broader population of people living with HIV.
A ordem abaixo segue uma estrutura editorial forte para SEO, experiência do usuário, E-E-A-T e conversão, adequada ao padrão do StrategicHealths.
❓ Frequently Asked Questions (FAQ)
Can stem cell therapy cure HIV?
Currently, stem cell transplantation is not considered a cure for HIV for the general population. A small number of individuals have achieved long-term HIV remission after receiving hematopoietic stem cell transplants from donors carrying the rare CCR5-Δ32 mutation, but these procedures were performed to treat life-threatening blood cancers rather than HIV itself.
What is the CCR5-Δ32 mutation?
CCR5-Δ32 is a rare genetic mutation that reduces or eliminates the expression of the CCR5 receptor on immune cells. Since many HIV strains rely on this receptor to infect CD4+ T cells, individuals with two copies of the mutation have a high degree of natural resistance to these viral strains.
Who were the Berlin and London patients?
The Berlin Patient (Timothy Ray Brown) and the London Patient (Adam Castillejo) are two of the best-known individuals who achieved long-term HIV remission after receiving hematopoietic stem cell transplants from CCR5-Δ32 donors while being treated for blood cancers. Their cases demonstrated that a functional HIV cure is biologically possible under exceptional circumstances.
Why isn’t stem cell transplantation used routinely for HIV?
Stem cell transplantation carries significant risks, including severe infections, graft-versus-host disease, organ toxicity and transplant-related mortality. Because modern antiretroviral therapy is highly effective and much safer, transplantation is reserved for selected patients who require it for other serious medical conditions.
Can gene editing replace stem cell transplantation?
Gene-editing technologies such as CRISPR are being investigated as a safer way to create HIV-resistant immune cells or target viral DNA directly. While early research is promising, these approaches remain experimental and are not currently approved as routine HIV treatments.
Is there a cure for HIV today?
There is no widely available cure for HIV. However, advances in stem cell biology, gene editing, immunotherapy and therapeutic vaccines continue to bring researchers closer to the goal of achieving long-term remission without lifelong antiretroviral therapy.
📌 Clinical Perspective
The rare cases of long-term HIV remission following hematopoietic stem cell transplantation have transformed our understanding of what may be biologically possible. Nevertheless, these exceptional outcomes occurred under highly specific clinical circumstances involving patients with serious hematological malignancies and carefully selected donors carrying the CCR5-Δ32 mutation.
For the vast majority of people living with HIV, antiretroviral therapy (ART) remains the safest, most effective and evidence-based treatment, enabling viral suppression, preventing transmission and providing life expectancy approaching that of the general population.
The scientific importance of these transplant cases lies not in establishing a new standard of care, but in guiding future research toward safer and more scalable strategies capable of achieving durable HIV remission.
🏁 Conclusion
Stem cell transplantation has fundamentally changed the landscape of HIV cure research by demonstrating that long-term viral remission is possible under exceptional conditions. Landmark cases such as the Berlin, London and Düsseldorf patients have provided invaluable insights into the role of the CCR5-Δ32 mutation, immune system replacement and viral reservoir reduction.
Despite these remarkable achievements, hematopoietic stem cell transplantation remains a high-risk procedure that is appropriate only for a very small group of patients with specific medical indications. Consequently, it cannot currently be considered a practical cure for the millions of people living with HIV worldwide.
The future of HIV cure research is increasingly focused on combining innovative technologies—including gene editing, engineered immune cells, broadly neutralizing antibodies, therapeutic vaccines, latency-targeting strategies and artificial intelligence—to develop treatments that are both effective and broadly accessible.
Although important challenges remain, ongoing scientific advances continue to strengthen optimism that long-term HIV remission, and perhaps one day a scalable cure, may become an achievable reality.
🔗 Recommended Articles
Continue exploring evidence-based medicine with these related StrategicHealths guides:
- 🧬 The Future of Regenerative Medicine: Gene Editing, Tissue Engineering and Beyond (2026)
- 🧬 Stem Cell Therapy for Amyotrophic Lateral Sclerosis (ALS): Current Scientific Evidence, Clinical Trials and Future Perspectives (2026)
- 🧠 Chronic Inflammation Explained: Causes, Health Risks and Evidence-Based Treatments (2026)
- 🦠 Oxidative Stress Explained: Mechanisms, Diseases and Evidence-Based Prevention (2026)
- 🧬 Gene Editing Explained: CRISPR Technology, Medical Applications and Future Perspectives (2026)
📚 References
- Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. The Lancet. 2013.
- Gupta RK, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019.
- Hsu J, et al. HIV remission after allogeneic stem-cell transplantation. Nature Medicine. 2023.
- International AIDS Society (IAS). Towards an HIV Cure. Latest scientific reports.
- UNAIDS. Global AIDS Update. Latest edition.
- World Health Organization (WHO). HIV Fact Sheets and Global HIV Programme.
- U.S. National Institutes of Health (NIH). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.
- Centers for Disease Control and Prevention (CDC). HIV Treatment Overview.
- Eisinger RW, Fauci AS. Ending the HIV/AIDS pandemic. JAMA. 2018.
- Yukl SA, Siliciano RF. HIV latency and eradication strategies. Cold Spring Harbor Perspectives in Medicine.
- Lewin SR, et al. International AIDS Society global scientific strategy: Towards an HIV cure. Nature Medicine. 2021.
- Sengupta S, Siliciano RF. Targeting the latent HIV reservoir. Immunity. 2018.
- International Antiviral Society–USA Panel. Recommendations for HIV treatment and cure research.
- ClinicalTrials.gov. Ongoing HIV cure and gene-editing clinical trials.
- Nature Reviews Immunology. Recent advances in HIV immunotherapy and cure research.
Leave a Reply